Q-Line Biotech Ltd. (QBL) is engaged within the enterprise of growing, manufacturing and advertising and marketing of various vary of reagents (together with kits and POC units) & consumables and manufacturing, importing, distribution/provide of diagnostic tools for various diagnostic healthcare wants. The corporate provides diagnostic tools and IVD merchandise for various diagnostic healthcare wants since 2013 instantly or by way of its distributor/s majorly to diagnostic service suppliers, hospitals and medical schools.
The corporate has established its manufacturers over a interval of 12 years by way of its expertise, R & D, manufacturing capabilities and high quality assurance. The core segments of operations of the Firm in IVD Business embrace Medical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Gadgets & Rapids).
QBL’s key manufacturing segments embrace indigenous manufacturing of reagents together with Medical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Gadgets & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology tools’s & units. Additional through the Covid-19 pandemic, the corporate diversified its focus and with the technical collaboration of third-party institutes and thru its personal R&D staff developed a spread of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits and so on.
It’s analysis pushed firm engaged in growing and manufacturing a variety of reagents formulations used throughout varied IVD and diagnostic wants. The corporate leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /merchandise. Additional, for its sure Class of Reagent & tools’s and units manufacturing enterprise, the corporate has entered into technical collaboration with sure worldwide corporations. Underneath the settlement phrases, it undertakes the manufacturing of those Reagent and tools’s and units as per the technical collaboration and specs supplied by the companions or corporations.
With the assistance of those collaborations the tools and units adhere to strict high quality management, worldwide requirements and certifications. As of March 31, 2026, the corporate employed 19 personnel at R&D laboratories, which constituted 5.25% of its whole everlasting worker power. As of March 31, 2026, it had 362 workers on its payroll and extra 223 contract workers in varied departments.
Subject Particulars / Capital Historical past
The corporate is popping out with its maiden guide constructing route IPO of 6253200 fairness shares of Rs. 10 every to mobilize Rs. 214.48 cr. on the higher cap. The corporate has introduced a value band of Rs. 326 – Rs. 343 per share. The minimal software to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on Could 21, 2026, and can shut on Could 25, 2026. The IPO represent 26.81% of the post-IPO paid-up capital of the corporate. The shares will probably be listed on NSE SME Emerge. From the online proceeds of the IPO, it should make the most of Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for compensation/prepayment of sure borrowings, and the remaining for basic company functions.
The corporate raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in Could 2026, at Rs. 343 per share.
The IPO is collectively lead managed by Hem Securities Ltd., and Share India Capital Providers Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the problem. HEM group’s Hem Finlease Pvt. Ltd., is the market maker in addition to a syndicate member.
The corporate has issued preliminary fairness capital at par worth. It raised additional fairness shares within the value vary of Rs. 125 – Rs. 417 between March 2019 and Could 2026. It has additionally issued bonus shares within the ratio of two for 1 in March 2016, and 9 for 1 in August 2025. The common value of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.
Submit-IPO, firm’s present paid-up fairness capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based mostly on the higher band of the IPO pricing, the corporate is searching for a market cap of Rs. 800.16 cr.
IPO Lead Managers & Registrar
On the monetary efficiency entrance, for the final three fiscals, the corporate has (on a consolidated foundation) posted whole revenue/ web revenue, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a web revenue of Rs. 38.69 cr. on a complete revenue of Rs. 236.50 cr. Although it posted progress in its prime strains for the reported durations, its backside line posted inconsistency. For FY25, it posted decrease web revenue of Rs. 28.13 cr., and for 9M-FY26, although the highest line is Rs, 236.50 cr. it posted bumper revenue of Rs. 38.69 cr. in a pre-IPO interval, that not solely elevate eyebrows, but additionally concern over its sustainability going ahead. Regardless of increased different revenue for FY25, it marked decrease web following extra-ordinary merchandise of Rs. 16.97 cr. Its contingent legal responsibility stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its general borrowings of Rs. 242.57 cr. as of December 31, 2025, elevate concern.
For the final two fiscals, the corporate has reported a mean EPS of Rs. 25.00, and a mean RoNW of 23.17%. The difficulty is priced at a P/BV of two.44 primarily based on its NAV of Rs. 140.81 per share as of December 31, 2025, however its post-IPO NAV information is lacking from the provide paperwork.
If we attribute FY26 tremendous earnings to its post-IPO totally diluted paid-up fairness capital, then the asking value is at a P/E of 15.51, and primarily based on FY25 earnings, the P/E stands at 28.44. The difficulty seems totally priced, primarily based on its bumper earnings for 9M-FY26, which will not be sustained.
For the reported durations, the corporate has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of twenty-two.14%, 19.25%, 17.66%, 13.32%, respectively, for referred durations.
All quantities in Indian Rupees crores
The corporate has not paid any dividends for the reported durations of the provide doc. It’s going to undertake a prudent dividend coverage, primarily based on its monetary efficiency and future prospects.
Comparability with Listed Friends – for Fiscal 2025
As per the provide doc, the corporate has no listed friends to match with.
Service provider Banker’s Observe Document
The 2 service provider bankers related to this concern have dealt with 79 points previously three years, out of which 8 points closed under the problem value on itemizing date.
Conclusion – Apply for medium to long run
QBL is engaged within the enterprise of growing, manufacturing and advertising and marketing of various vary of reagents and consumables. It posted progress in its prime strains for the reported durations, however suffered a setback for FY25 in backside line following accounting changes. As the corporate has no listed friends, it’s making an attempt to extract fancy value for its IPO. Based mostly on its general monetary information, the problem seems totally priced. Properly-informed traders might park average funds for long run.
Dilip Davda is a veteran monetary journalist related to the Indian inventory market since 1978. He has been contributing to print and digital media on capital markets, insurance coverage, and finance since 1985.
He’s widely known for reviewing public points and non-convertible debentures (NCDs) within the major market. Drawing on over three a long time of market expertise and shut interplay with service provider bankers, his evaluations deal with detailed basic and monetary evaluation of corporations, with a particular emphasis on SME public points.
Disclaimer: The knowledge supplied herein is solely for academic and informational functions and doesn’t represent a proposal, solicitation, or suggestion to purchase or promote any securities. Readers are suggested to seek the advice of a professional monetary advisor earlier than making any funding choices. Investments within the securities market are topic to market dangers. The writer doesn’t intend to put money into the securities mentioned.
